Craig-Hallum Assumes NeoGenomics at Buy, Announces Price Target of $26
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Alex Nowark has initiated coverage on NeoGenomics (NASDAQ:NEO) with a Buy rating and set a price target of $26.

May 01, 2024 | 5:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeoGenomics receives a Buy rating from Craig-Hallum with a price target of $26.
The initiation of coverage by Craig-Hallum with a Buy rating and a price target significantly above the current trading price is likely to be viewed positively by investors, potentially driving short-term price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100